9 months after raising Rs 50 cr, firm to pursue legal action to recover Rs 8.16 cr vendor payment

The company had previously attempted listing in 2019 on the Emerge Platform of the National Stock Exchange, but it had pulled out on the last day of subscription "due to material changes in the current business model and future expansion plan"

Trade

• Watchlist
• Portfolio
• Message
• Set Alert

 

 

Choose Stock Exchange: BSE LIVE NSE LIVE

26 Aug, 2025 12:21

Volume

Todays L/H

More

×

Sudarshan Pharma, which was listed only nine months ago, has informed the exchanges that it will be pursuing legal action against one of its vendors.

The company raised a little over Rs 50 crore through its initial public offering (IPO) in March 2023.

According to an exchange filing dated January 2, the company had made an advance payment of around AED 35,99,048 (Rs 8.16 crore) to a vendor, who did not then deliver.

Also read: Market to be busy on January 3 as four companies scheduled for listing

The filing stated, "We made the advance payment of AED 35,99,048 to the Company named Regans International DMCC for import of chemicals but even after the passage of six months, the company Sudarshan Pharma Industries Limited was unable to receive the material."

It added, "As required by the RBI rules we are taking necessary legal recourse. We are in the process of either obtaining the material or demanding the refund of the advance payment."

One of the risk factors mentioned in its red-herring prospectus was its vendor agreements, which are not long-term agreements.

The prospectus read, "Our business may be adversely affected if there is any disruption in the trading material supply or due to non-availability of trading material. We do not have written agreements with our vendors/suppliers and we operate on a purchase order system. There are no long-term supply agreements for the trading material. In the absence of any such formal contract with our vendors/suppliers, we are exposed to the risks of irregular supplies or no supplies at all or delayed supplies or price variation which would materially affect our results of operations."

Also read: Top five most gained IPOs on listing day in 2023

It added, "In the event of any disruption in the supply or the nonavailability of material in the required quantity and of required quality from an alternate source, the supply schedule to our clients may be adversely affected impacting the sales and profitability of the company."

The company had previously attempted listing in 2019 on the Emerge Platform of the National Stock Exchange, but it had pulled out on the last day of subscription "due to material changes in the current business model and future expansion plan".